TOP STORIES — Diabetes News and Research
Oral Semaglutide + Basal Insulin
Letter from the Editor
This week our FAMU intern Brianna Belton has a great feature on the use of a new medical app to help track and treat depression. The app looks at steps and text messaging to determine depression levels. I am reminded of Aaron Burr’s line from the hit show Hamilton: “Depress less; walk more.” Well, that was not exactly what he said, but if Lin-Manuel Miranda can take some poetic liberty then so can I.
I may have been reminded of that phrase while I was reading the feature and saw the mention that results were based in part on the HAM-A (Hamilton Anxiety Rating Scale). This app may turn out to be a great one to use as more of our patients are having problems with anxiety and depression, and the opportunity to see a mental health professional is decreased.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES -- Diabetes News and Research
Analysis of the PIONEER 8 trial reveals dose-dependent reductions in A1c and body weight when oral semaglutide is paired with various insulin regimens.
The do-it-yourself artificial pancreas systems (DIYAPS) offer a solution to patients who lack access to, or can’t afford, other technological options.
A high percentage of people with diabetes also suffer from depression, and professionals need to be aware of things that they can do to help.
Did You Know? Taller Children May Have Increased Risk for Type 2:
Taller children are more likely to have a higher body mass index than shorter children, which can increase the risk for T2D, according to a study done on children between 2 and 13.8 years of age. Several cross‐sectional studies have shown that height in childhood is correlated with BMI and with body fatness, and two longitudinal studies have reported that childhood height is associated with adult BMI. This study, published (July 2020) in the journal Obesity, explored this longitudinal association in an electronic health record database of 2.8 million children.
The researchers concluded that children who are relatively tall for their age have a higher risk of developing obesity and eventually a higher risk for diabetes. When they were re-examined, an average of 4 years later (but up to 13 years later), it was found that taller children were more likely to have a higher body mass index than shorter children. For example, among the thinnest children at the start, the prevalence of obesity at the second exam was 5-fold higher in the tallest children than in the shortest children (3.1 percent versus 0.6 percent). Among the heaviest children at the start, the respective prevalence rates of obesity were 89.5 percent versus 53.4 percent. According to the lead author David S Freedman, Ph.D., of the Centers for Disease Control and Prevention, “Height may be a simple way to classify which children will become obese accurately.”
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Brianna Belton, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences
Lawand Kamal, PharmD Candidate 2021, Skaggs School of Pharmacy and Pharmaceutical Sciences
Sameen Khan, Pharm.D. Candidate, USF College of Pharmacy
Maya Palmer, PharmD. Candidate, Florida A&M University College of Pharmacy
Stephen Rubano, PharmD. Candidate, USF Taneja College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com